A study of the use of the Provant Infinity Therapy System when treatment is administered 30 minutes twice daily for 8-weeks (56 days ± 3 days) at home for postoperative pain.
This is an 8-week (56 days ± 3 days), multi-center, open label clinical trial conducted on subjects with chronic postoperative pain. Eligible subjects will include those between 22 and 80 years of age with chronic postoperative pain at least 60 days following surgery. At the Screening Visit, eligible subjects will have an average weekly pain score, over the last 7 days of ≥4 and \<9 based on the 11-point NPRS (0-10) and will verbally confirm they have chronic postoperative pain from surgery ≥ 60 days prior . After signing Informed Consent and verifying subject eligibility for the trial (including a pain score assessment using the NPRS), subjects will have demographic information, medical/surgical history and medication use reviewed and recorded. An abbreviated physical examination, including height and weight, will be performed. A urine pregnancy test will be performed on women of childbearing potential. Screening and Baseline (Day 0) / Enrollment may occur on the same day. During the Enrollment visit, subjects will receive study device training and be dispensed a study device with instructions to self-treat twice daily (morning and evening; 8am ± 2 hours and 8pm ± 2 hours) for 8 weeks (56 days ± 3 days). If Screening and Enrollment are not on the same day, subjects returning to the clinic for Baseline (Day 0) will have an additional review of eligibility, medical history, adverse events and concomitant medications prior to device training and dispensation. Subjects will receive a telephone call at Week 2 / Day 14 (±3 days). During the phone call subjects will have adverse events, and concomitant medications reviewed. Average weekly pain score (using the NPRS), Patient Global Impression (PGI), Treatment Satisfaction and Device Use questions will be captured. Subjects will receive a telephone call at Week 4 / Day 28 (±3 days). During the phone, call subjects will have adverse events, and concomitant medications reviewed. Average weekly pain score (using the NPRS), Patient Global Impression (PGI), Treatment Satisfaction and Device Use questions will be captured. Subjects will receive a telephone call at Week 6 / Day 42 (±3 days). During the phone, call subjects will have adverse events, and concomitant medications reviewed. Average weekly pain score (using the NPRS), Patient Global Impression (PGI), Treatment Satisfaction and Device Use questions will be captured. At the Week 8 / Day 56 (±3 days) End of Study Visit, subjects will have adverse events and concomitant medications reviewed. Average weekly pain score (using the NPRS), Patient Global Impression (PGI), Treatment Satisfaction and Device Use and Feedback questions will be captured and the study device will be returned.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Treatment with the Provant Infinity Therapy System, PEMF device
Physician's Research Group
Mesa, Arizona, United States
Valley Clinical Research
Northridge, California, United States
Lake Internal Medicine Associates
Eustis, Florida, United States
Palm Research Center
Las Vegas, Nevada, United States
Device Use Questionnaire
4 question questionnaire on device usage (total of all responses will be counted at the end of the study); response will require a "Yes" or "No" answer
Time frame: Week 8
Device Feedback Questionnaire
5 question questionnaire about the study device; device use questions will be open text, "Yes" or "No" answers or rated from "Extremely Easy/Extremely Comfortable" to "Extremely Difficult/Extremely Uncomfortable"
Time frame: Week 8
Numeric Pain Rating Scale (NPRS)
11-point numerical rating scale for pain (0 = no pain to 10 = worst possible pain)
Time frame: Weeks 2, 4, 6 and 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.